USX:PRVL - Prevail Therapeutics Inc (USD 13.97) Prevail Therapeutics Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance

USD 13.97    +0.240 (+1.75%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


Overview

9 Apr 2020

Day Change: 0.240 (1.75%)

52 Wk Range: 7.41 - 19.25

Day's Range: 13.85 - 15.101

Last Volume: 98,821

Current Yield: 0%

Projected Yield: 0%

Open: USD 14.98

9 Apr 2020

Metric PRVL S.Median
Beta 0.96 0.84
VaR 62.98 25.23
E.Shortfall 74.64 45.03
Liquidity 111.55K 95.2K

Fundamental


More from Yahoo

General

CEO: Asa Abeliovich

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

Prevail Therapeutics Inc is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. They are applying a precision medicine approach to neurodegeneration by studying gene therapies in genetically defined patient populations. They believe this will increase the probability of creating disease-modifying therapies that improve patients’ lives. Their lead program is PR001 for the treatment of Parkinson’s disease with GBA1 mutation, or PD-GBA, and neuronopathic Gaucher disease. They are focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc incorporated under the laws of the State of Delaware in July 2017. Their principal executive offices are located at 430 East 29th Street, Suite 940, New York, New York 10016.